Ardelyx Inc (NASDAQ: ARDX)’s stock price has gone decline by -2.20 in comparison to its previous close of 4.55, however, the company has experienced a -9.37% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-03-31 that WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that an abstract detailing a post-hoc analysis of the OPTIMIZE Study, an open-label clinical trial of XPHOZAH ® (tenapanor), was accepted as a poster presentation at the National Kidney Foundation (NKF) Spring Clinical Meetings, to be held April 10-13, 2025, in Boston.
Is It Worth Investing in Ardelyx Inc (NASDAQ: ARDX) Right Now?
The 36-month beta value for ARDX is at 0.78. Analysts have varying views on the stock, with 9 analysts rating it as a “buy,” 0 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ARDX is 230.57M, and currently, shorts hold a 13.17% of that float. The average trading volume for ARDX on April 08, 2025 was 4.31M shares.
ARDX’s Market Performance
ARDX’s stock has seen a -9.37% decrease for the week, with a -16.04% drop in the past month and a -10.46% fall in the past quarter. The volatility ratio for the week is 6.37%, and the volatility levels for the past 30 days are at 5.55% for Ardelyx Inc The simple moving average for the last 20 days is -13.21% for ARDX’s stock, with a simple moving average of -20.62% for the last 200 days.
Analysts’ Opinion of ARDX
BTIG Research, on the other hand, stated in their research note that they expect to see ARDX reach a price target of $14. The rating they have provided for ARDX stocks is “Buy” according to the report published on March 04th, 2025.
H.C. Wainwright gave a rating of “Neutral” to ARDX, setting the target price at $5.50 in the report published on November 11th of the previous year.
ARDX Trading at -16.56% from the 50-Day Moving Average
After a stumble in the market that brought ARDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.30% of loss for the given period.
Volatility was left at 5.55%, however, over the last 30 days, the volatility rate increased by 6.37%, as shares sank -15.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.38% lower at present.
During the last 5 trading sessions, ARDX fell by -9.37%, which changed the moving average for the period of 200-days by -25.21% in comparison to the 20-day moving average, which settled at $5.13. In addition, Ardelyx Inc saw -12.23% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARDX starting from Rosenbaum David P., who proposed sale 44,330 shares at the price of $5.47 back on Mar 17 ’25. After this action, Rosenbaum David P. now owns shares of Ardelyx Inc, valued at $242,559 using the latest closing price.
RAAB MICHAEL, the President & CEO of Ardelyx Inc, sale 41,668 shares at $5.36 during a trade that took place back on Mar 07 ’25, which means that RAAB MICHAEL is holding 1,635,138 shares at $223,199 based on the most recent closing price.
Stock Fundamentals for ARDX
Current profitability levels for the company are sitting at:
- -0.08 for the present operating margin
- 0.85 for the gross margin
The net margin for Ardelyx Inc stands at -0.12. The total capital return value is set at -0.08. Equity return is now at value -23.01, with -10.67 for asset returns.
Based on Ardelyx Inc (ARDX), the company’s capital structure generated 0.47 points at debt to capital in total, while cash flow to debt ratio is standing at -0.29. The debt to equity ratio resting at 0.89. The interest coverage ratio of the stock is -1.39.
Currently, EBITDA for the company is -16.71 million with net debt to EBITDA at -5.3. When we switch over and look at the enterprise to sales, we see a ratio of 3.44. The receivables turnover for the company is 5.78for trailing twelve months and the total asset turnover is 0.77. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.58.
Conclusion
In conclusion, Ardelyx Inc (ARDX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
